Shenzhen Bioeasy Biotechnology Co. Ltd. Tangible Net Worth Ratio
Shenzhen Bioeasy Biotechnology Co. Ltd. tangible net worth ratio. Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) has a Tangible Net Worth Ratio of 95.9% as of March 2026. This metric is calculated by deducting intangible assets (CN¥36.86 Million) from net assets (CN¥899.42 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 300942 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2025)
Tangible net worth ratio of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2025. This chart shows how Shenzhen Bioeasy Biotechnology Co. Ltd.'s Tangible Net Worth Ratio has changed across 10 annual periods from 2016 to 2025. As of March 2026, the ratio stands at 95.9%, reflecting net assets of CN¥899.42 Million with intangible assets of CN¥36.86 Million CNY. Check 300942 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Shenzhen Bioeasy Biotechnology Co. Ltd. Tangible Net Worth Ratio by Year (2016–2025)
Shenzhen Bioeasy Biotechnology Co. Ltd. tangible net worth ratio by year from 2016 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2025, covering 10 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see how much is Shenzhen Bioeasy Biotechnology Co. Ltd. worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 95.9% | CN¥907.68 Million | CN¥37.35 Million | CN¥1.52 Billion | ▲ +0.4 pp |
| 2024 | 95.5% | CN¥870.24 Million | CN¥39.24 Million | CN¥1.46 Billion | ▲ +0.4 pp |
| 2023 | 95.1% | CN¥848.73 Million | CN¥41.39 Million | CN¥1.36 Billion | ▼ -0.5 pp |
| 2022 | 95.6% | CN¥964.70 Million | CN¥42.40 Million | CN¥1.28 Billion | ▲ +0.1 pp |
| 2021 | 95.5% | CN¥946.58 Million | CN¥42.60 Million | CN¥1.15 Billion | ▲ +3.5 pp |
| 2020 | 92.0% | CN¥548.98 Million | CN¥44.12 Million | CN¥652.89 Million | ▼ -7.8 pp |
| 2019 | 99.7% | CN¥528.32 Million | CN¥1.36 Million | CN¥619.67 Million | ▲ +0.1 pp |
| 2018 | 99.7% | CN¥222.62 Million | CN¥724.65K | CN¥296.83 Million | ▲ +0.0 pp |
| 2017 | 99.7% | CN¥114.60 Million | CN¥398.15K | CN¥173.80 Million | ▼ -0.3 pp |
| 2016 | 99.9% | CN¥55.24 Million | CN¥37.98K | CN¥123.07 Million | — |